Back

Developing Provider-Co-Created Prototypes Addressing Equity-Related Barriers in Liver Transplantation for Hepatocellular Carcinoma"

Nephew, L.; Moore, C.; Garcia, N.; Parks, L.; McKay, A.; Abad, S.; Rawl, S.

2026-05-21 gastroenterology
10.64898/2026.05.15.26353301 medRxiv
Show abstract

Background: Black patients and individuals with low socioeconomic status (SES) face significant disparities in accessing curative therapies for hepatocellular carcinoma (HCC), including liver transplantation. This study aimed to develop provider-co-created intervention prototypes in response to patient-identified barriers and recommendations. Methods: A human-centered design session with hepatology and transplant providers at a large academic medical center was conducted. Prior to the session, participants were presented with barriers and preliminary solutions identified through an earlier human-centered design session with Black and low-SES patients. Using structured ideation methods, including brainwriting, challenge mapping, and concept voting, providers co-created intervention prototypes. Final concepts were synthesized from patient insights, provider input, and design methods using affinity diagramming and concept modeling. Results: Nine providers participated in the session. They focused on three key areas for intervention: inefficiencies in transplant pre-evaluation, inadequate social support, and information overload. Solutions included: (1) a structured triage pathway to standardize referrals and reduce delays; (2) a peer navigator model to guide patients through the transplant process; and (3) a multimodal transplant education roadmap to improve comprehension and engagement. These prototypes addressed both patient- and system-level barriers. Conclusions: Protypes developed through provider-led design, grounded in patient-identified barriers and co-created ideas, can yield actionable, scalable strategies to advance equity in HCC care. Future work will refine these prototypes through patient feedback and pilot them in clinical settings.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
PLOS ONE
5266 papers in training set
Top 13%
13.5%
2
Contemporary Clinical Trials Communications
11 papers in training set
Top 0.1%
13.3%
3
Hepatology
22 papers in training set
Top 0.1%
8.3%
4
Frontiers in Medicine
120 papers in training set
Top 0.6%
4.2%
5
Microbial Cell Factories
27 papers in training set
Top 0.2%
3.4%
6
Medicine
31 papers in training set
Top 0.4%
3.4%
7
Frontiers in Psychology
56 papers in training set
Top 0.3%
3.4%
8
Journal of Medical Internet Research
87 papers in training set
Top 0.9%
2.9%
50% of probability mass above
9
BMJ Open
601 papers in training set
Top 7%
2.8%
10
Journal of Clinical and Translational Science
14 papers in training set
Top 0.1%
2.5%
11
Heliyon
152 papers in training set
Top 2%
2.1%
12
Scientific Reports
3612 papers in training set
Top 52%
1.8%
13
JMIR Research Protocols
21 papers in training set
Top 0.5%
1.8%
14
iScience
1154 papers in training set
Top 16%
1.8%
15
Vaccines
198 papers in training set
Top 2%
1.8%
16
F1000Research
88 papers in training set
Top 1%
1.8%
17
PLOS Digital Health
106 papers in training set
Top 2%
1.8%
18
Journal of Clinical Medicine
97 papers in training set
Top 3%
1.6%
19
Clinical and Translational Science
22 papers in training set
Top 0.3%
1.4%
20
Hepatology Communications
22 papers in training set
Top 0.3%
1.2%
21
American Journal of Gastroenterology
17 papers in training set
Top 0.3%
1.2%
22
BMC Medical Research Methodology
47 papers in training set
Top 0.9%
1.2%
23
Biomolecules
100 papers in training set
Top 2%
1.0%
24
Cureus
68 papers in training set
Top 4%
0.9%
25
JAMIA Open
42 papers in training set
Top 1%
0.9%
26
Frontiers in Oncology
103 papers in training set
Top 3%
0.9%
27
PeerJ
308 papers in training set
Top 12%
0.6%
28
American Journal of Preventive Medicine
11 papers in training set
Top 0.3%
0.6%
29
Nature Communications
5641 papers in training set
Top 58%
0.6%
30
Communications Medicine
113 papers in training set
Top 5%
0.6%